On (b)(6) 2024, during a follow up, a hospital peritoneal dialysis registered nurse [(pd)rn] reported to fresenius this peritoneal dialysis (pd) patient on continuous cyclic pd (ccpd) therapy utilizing the liberty select cycler was hospitalized for peritonitis.There was no specific allegation this adverse event was related to a deficiency or malfunction of any fresenius product(s) or device(s) in the initial reporting.Upon follow up with the patient¿s pdrn, it was reported this patient was hospitalized on (b)(6) 2024 following abdominal pain and cloudy peritoneal effluent fluid.Peritoneal effluent fluid cultures taken in the hospital on (b)(6) 2024 presented with klebsiella pneumoniae and a white blood cell (wbc) count of 9271/mm3.The patient was diagnosed with peritonitis due to touch contamination during ccpd therapy on the liberty select cycler at home.The patient was prescribed intraperitoneal (ip) vancomycin and ip ceftazidime initially (unknown dosages and frequency), but the antibiotic was changed to ip meropenem (dosage and frequency unknown) as they experienced nausea with other antibiotics.The patient was able to undergo ccpd therapy on a hospital provided liberty cycler for the duration of the admission.The patient had an uneventful hospital course and was discharged to home on (b)(6) 2024.It was confirmed the patient¿s peritonitis, and the associated hospitalization were not due to a deficiency or malfunction of any fresenius product(s) or device(s).The patient recovered from this event as he remains asymptomatic and continues ccpd therapy on the same liberty select cycler at home.
|